CEBP http://www.cancermicroenvironment.tau.ac.il/welcome2009.html Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Epidemiology Biomarkers & Prevention 17, 459, February 1, 2008. doi: 10.1158/1055-9965.EPI-07-2776
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldstein, M. R.
Right arrow Articles by Pezzetta, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldstein, M. R.
Right arrow Articles by Pezzetta, F.
Related Collections
Right arrowRelated Article

Letter

How Statins May Increase Prostate Cancer

Mark R. Goldstein

Fountain Medical Court, Bonita Springs, Florida

Luca Mascitelli

Comando Brigata Alpina "Julia," Servizio Sanitario, Udine, Italy

Francesca Pezzetta

Cardiology Service, Ospedale di San Vito al Tagliamento, San Vito al Tagliamento, Italy

To the Editors: We read Dr. Platz's excellent editorial on statins in the prevention of prostate cancer, and we agree with her conclusion that it is premature to recommend statins for the prevention of advanced prostate cancer (1). However, there are recent data suggesting that statins may actually increase prostate cancer and also impair prostate cancer immunotherapy.

Long-term follow-up of the West of Scotland Coronary Prevention Study, a primary prevention trial involving middle aged men, showed a significant increase in prostate cancer among those men randomized to pravastatin compared with placebo (2). This is biologically plausible.

Interestingly, statins have been found to increase the number of CD4+CD25+ regulatory T cells (Treg) in vivo by inducing the transcription factor forkhead box P3 (3). Tregs impair host antitumor response by suppressing tumor-specific T-cell responses, which leads to increased cancer risk (4).

Indeed, Tregs have been reported to be increased in prostate cancer tissue compared with normal prostate tissue from the same prostate, and the concentration of Tregs in peripheral blood has been found to be higher in prostate cancer patients than in normal donors (5). Furthermore, a statin-induced increase in Tregs, favoring tumor escape, may exert a detrimental effect during cancer immunotherapy (6).

Therefore, there are data suggesting that statins may increase prostate cancer risk by increasing the concentration of Tregs. This needs our attention, given the widespread and increasing use of statins at higher doses in segments of the population already at risk for prostate cancer.


    References
 Top
 References
 

  1. Platz EA. Epidemiologic musing on statin drugs in the prevention of advanced prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:2175–80.[Free Full Text]
  2. West of Scotland Coronary Prevention-Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477–86.[Abstract/Free Full Text]
  3. Mausner-Fainberg K, Luboshits G, Mor A, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis. Epub 2007 Sept 10.
  4. Yakirevich E, Resnick MB. Regulatory T lymphocytes: pivotal components of the host antitumor response. J Clin Oncol 2007;25:2506–8.[Free Full Text]
  5. Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177:7398–405.[Abstract/Free Full Text]
  6. O'Mahony D, Morris JC, Quinn C, et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 2007;13:958–64.[Abstract/Free Full Text]

Related Article

Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer
Elizabeth A. Platz
Cancer Epidemiol. Biomarkers Prev. 2007 16: 2175-2180. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Am J EpidemiolHome page
I. Agalliu, C. A. Salinas, P. D. Hansten, E. A. Ostrander, and J. L. Stanford
Statin Use and Risk of Prostate Cancer: Results from a Population-based Epidemiologic Study
Am. J. Epidemiol., August 1, 2008; 168(3): 250 - 260.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldstein, M. R.
Right arrow Articles by Pezzetta, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldstein, M. R.
Right arrow Articles by Pezzetta, F.
Related Collections
Right arrowRelated Article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online